Loading…
Anavex Life Sciences Corp. is projected to decline to $2.69 by 2027, a -2% move from its current price of $2.75. AVXL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.66 | $2.75 | $2.85 | +0.05% |
| Aug 4 | $2.62 | $2.75 | $2.89 | +0.09% |
| Aug 5 | $2.59 | $2.75 | $2.92 | +0.14% |
| Aug 6 | $2.57 | $2.75 | $2.95 | +0.18% |
| Aug 7 | $2.55 | $2.76 | $2.98 | +0.23% |
| Aug 8 | $2.54 | $2.76 | $3.00 | +0.27% |
| Aug 9 | $2.52 | $2.76 | $3.02 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.52 | $2.76 | $3.02 | +0.32% |
| Week 2 | $2.43 | $2.77 | $3.15 | +0.64% |
| Week 3 | $2.37 | $2.78 | $3.25 | +0.96% |
| Week 4 | $2.32 | $2.79 | $3.34 | +1.28% |
| Week 5 | $2.28 | $2.79 | $3.42 | +1.60% |
| Week 6 | $2.24 | $2.80 | $3.50 | +1.92% |
| Week 7 | $2.21 | $2.81 | $3.58 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice. Anavex Life Sciences Corp.
was incorporated in 2004 and is headquartered in New York, New York.
AVXL is the healthcare-focused biotechnology stock of Anavex Life Sciences Corp., with a current price of $2.70 and a market capitalization of $250.21M. It ranks 3427 by market cap among listed equities. The asset sits in the Healthcare category and carries a bullish near-term bias in its technical picture, with a forward-looking multi-year forecast that shows a path toward higher values later in the horizon.
The forecasted path projects modest to meaningful upside over time, starting from a near-term base through 2029, then accelerating in the 2030s and into 2050. The forecast lists yearly average prices and ROI figures, illustrating a long-run upward trajectory while highlighting near-term neutrality in several early years before a bullish stance emerges in the 2030s and beyond.
A major floor 20.1% below — a decisive break under it would weaken the trend.
The nearest floor, 14.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.4% away) — a breakout level to watch.
A major ceiling 52.4% above — clearing it would confirm fresh momentum.
Key AVXL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVXL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.60 | Buy | $2.63 | Buy |
| MA 10 | $2.54 | Buy | $2.57 | Buy |
| MA 20 | $2.53 | Buy | $2.56 | Buy |
| MA 50 | $2.61 | Buy | $2.69 | Buy |
| MA 100 | $3.03 | Sell | $3.13 | Sell |
| MA 200 | $4.05 | Sell | $4.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.87 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 132.59 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 10.00 | Buy |
| Bollinger %B (20,2) | 0.93 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.23 | Sell |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 64.13 | Neutral |
| Momentum (10) | 0.36 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 2.67 | Buy |
| ADX (14) | 11.52 | Neutral |
| ATR (14) | 0.09 | Info |
The current technical picture is described as BULLISH, with an RSI14 of 60. The 50-day simple moving average (SMA50) is $2.61 and the 200-day simple moving average (SMA200) is $4.08. Key support sits at $2.34 and resistance at $2.76, framing a near-term dynamic.
The 30-day price range is from $2.14 to $3.40, indicating the stock has traded within a relatively tight band recently.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.34 | $2.75 | $3.53 | 0% | Neutral | |
| $2.10 | $2.69 | $3.68 | -2% | Neutral | |
| $2.20 | $2.93 | $4.20 | +7% | Neutral | |
| $2.13 | $2.93 | $4.34 | +6% | Neutral | |
| $2.16 | $3.04 | $4.64 | +11% | Neutral | |
| $2.79 | $4.02 | $6.31 | +46% | Bullish | |
| $2.89 | $4.28 | $6.86 | +56% | Bullish | |
| $2.91 | $4.40 | $7.20 | +60% | Bullish | |
| $2.96 | $4.57 | $7.62 | +66% | Bullish | |
| $2.59 | $4.07 | $6.91 | +48% | Bullish | |
| $3.88 | $6.69 | $12.20 | +143% | Bullish | |
| $6.68 | $13.58 | $27.50 | +394% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.34 | $2.75 | $3.33 | +0.00% |
| September 2026 | $2.31 | $2.76 | $3.39 | +0.29% |
| October 2026 | $2.38 | $2.87 | $3.57 | +3.92% |
| November 2026 | $2.38 | $2.88 | $3.63 | +0.48% |
| December 2026 | $2.28 | $2.78 | $3.53 | -3.63% |
Click any year to see its month-by-month AVXL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AVXL to range from $2.34 to $3.53 through 2026. The $2.75 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The AVXL price prediction for 2027 points to an average of $2.69 (low $2.10, high $3.68) — a potential decline of -2% on today's $2.75. A consolidation phase looks the most probable path here.
In 2028, AVXL is projected to trade between $2.20 and $4.20, averaging $2.93 — a potential gain of +7% from today's $2.75. That is up +9% on the projected 2027 average. Price action looks broadly range-bound.
Anavex Life Sciences Corp.'s 2029 outlook centres on $2.93, within a $2.13 to $4.34 range. That is 0% versus the projected 2028 average. That marks a +6% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, AVXL could reach as high as $4.64, with a base case around $3.04 and support toward $2.16 — roughly +11% from $2.75. Price action looks broadly range-bound.
Expect AVXL to range from $2.79 to $6.31 through 2031. The $4.02 average target implies a +46% move from current prices. That is up +32% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The AVXL price prediction for 2032 points to an average of $4.28 (low $2.89, high $6.86) — a potential gain of +56% on today's $2.75. Momentum favours further upside here.
In 2033, AVXL is projected to trade between $2.91 and $7.20, averaging $4.40 — a potential gain of +60% from today's $2.75. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Anavex Life Sciences Corp.'s 2034 outlook centres on $4.57, within a $2.96 to $7.62 range. That is up +4% on the projected 2033 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2035, AVXL could reach as high as $6.91, with a base case around $4.07 and support toward $2.59 — roughly +48% from $2.75. Buyers look set to stay in control over this stretch.
Expect AVXL to range from $3.88 to $12.20 through 2040. The $6.69 average target implies a +143% move from current prices. That is up +64% on the projected 2035 average. Momentum favours further upside here.
The AVXL price prediction for 2050 points to an average of $13.58 (low $6.68, high $27.50) — a potential gain of +394% on today's $2.75. Buyers look set to stay in control over this stretch.
Investing $1,000 in AVXL today (≈ 363.636364 AVXL) could be worth
$4,939.47
+$3,939.47 (+394%) by 2050 · US Dollar
Based on the average projected AVXL price of $13.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVXLwould be worth at today's price.
$1,000 invested in AVXL on Jul 31, 2025 (≈ 88.495574 AVXL) would be worth
$243.36
-$756.64 (-75.7%) today · 0.24× · US Dollar
Based on a AVXL entry price of $11.3 vs. today's $2.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.4 | $1,145.83 | +14.6% |
| 1 month ago | $2.58 | $1,065.89 | +6.6% |
| 3 months ago | $3.32 | $828.31 | -17.2% |
| 6 months ago | $4.52 | $608.41 | -39.2% |
| 1 year ago | $11.3 | $243.36 | -75.7% |
| All time (5.0y) ago | $17.95 | $153.2 | -84.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVXL forecast.
Our base-case forecast reaches $5.50 around 2040.
Implied market cap at $5.50: $509.69M
The multi-year forecast shows a progression from neutral to bullish momentum over time. The 2026–2029 window carries neutral sentiment with average prices of $2.70, $2.67, $2.92, and $2.93 respectively and ROIs of 0, -1.1, 8, and 8.6. By 2031 the forecast turns bullish, with an average price of $4.13 and ROI of 53, followed by 2032 at $4.39 with ROI 62.4, 2033 at $4.52 with ROI 67.5, 2034 at $4.70 with ROI 73.9, and 2035 at $4.20 with ROI 55.4, all marked as BULLISH sentiment.
Beyond the mid-decade, the forecast shows continued upside: 2040 average $7.01 with ROI 159.5 and 2050 average $14.49 with ROI 436.5, both still labeled BULLISH. The implied path suggests a substantial longer-run upside relative to the early years, though these figures are estimates and not guarantees. As with any forecast, actual results may vary and investors should consider the inherent uncertainty of long-horizon projections.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.10, with a min of $2.19 and a max of $4.77, and an ROI of 14.9.
The forecast lists NEUTRAL sentiment through 2030, with the average price moving from $2.70 in 2026 to $3.10 in 2030, and later years showing higher upside (2031 avg $4.13, ROI 53; 2050 avg $14.49, ROI 436.5). However, ROI figures are estimates and not guarantees.
Yes. The forecast maximum in 2030 is $4.77, and the 2031 max is $6.52, with further upside in 2034 max $7.89, indicating that a $3 target is within the predicted range.
The 30-day range is $2.14 to $3.40.
In 2040, the forecast shows an average price of $7.01, with a min of $4.01 and a max of $12.90, and an ROI of 159.5, with sentiment BULLISH.
Anavex Life Sciences Corp. Community Discussion
0Share your Anavex Life Sciences Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.